Company corrects to clarify its U.S. staff is larger than in Switzerland or Germany (not larger than in the two countries combined
FRANKFURT, Jan 30 (Reuters) - Roche's ROG.S CEO said on Thursday that the Swiss drugs and diagnostics group's major production sites in the United States prepare it well for the prospect of trade tariffs raised by President Donald Trump.
"We have a significant manufacturing footprint in the U.S. and we will continue to expand on that ... We are very well positioned in this regard, whatever happens," CEO Thomas Schinecker said in a media call.
He added that Roche had invested 11 billion Swiss francs ($12.1 billion) in the U.S. over the last 10 years and, with a U.S. headcount of 25,000, it has more staff there than it has in Switzerland or in Germany.
($1 = 0.9067 Swiss francs)